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ABSTRACT
The optimal duration of antibiotic treatment for acute exacerbations of chronic obstructive pulmonary
disease (AECOPD) is unknown. This study compared the outcome of treatment for 3 vs. 10 days with
amoxycillin–clavulanic acid of hospitalised patients with AECOPD who had improved substantially
after initial therapy for 3 days. Between November 2000 and December 2003, 56 patients with AECOPD
were enrolled in the study. Unfortunately, because of the low inclusion rate, the trial was discontinued
prematurely. Patients were treated with oral or intravenous amoxycillin–clavulanic acid. Patients who
showed improvement after 72 h were randomised to receive oral amoxycillin–clavulanic acid 625 mg or
placebo, four times daily for 7 days. The primary outcome measure of the study was clinical cure after
3 weeks and 3 months. Of 46 patients included in the ﬁnal analysis, 21 were in the 3-day treatment
group and 25 were in the 10-day treatment group. After 3 weeks, 16 (76%) of 21 patients in the 3-day
treatment group were cured, compared with 20 (80%) of 25 in the 10-day treatment group (difference
)3.8%; 95% CI )28 to 20). After 3 months, 13 (62%) of 21 patients were cured, compared with 14 (56%)
of 25 (difference 5.9%; 95% CI )23 to 34). Microbiological success, symptom recovery, the use of
corticosteroids, the duration of oxygen therapy and the length of hospital stay were comparable for both
treatment groups. It was concluded that 3-day treatment with amoxycillin–clavulanic acid can be a safe
and effective alternative to the standard 10-day treatment for hospitalised patients with AECOPD who
have improved after initial therapy for 3 days.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
affects 3–17% of the adult population in devel-
oped countries [1], with rising morbidity and
mortality rates [2,3] (http://www.goldcopd.com).
Antibiotic therapy is indicated for cases with
severe acute exacerbations of COPD (AECOPD),
characterised by an increase in dyspnoea and the
volume and purulence of sputum [4–6]. The
optimal duration of antibiotic therapy in such
cases is unknown. Most recent guidelines do not
mention the duration of therapy [7] (http://
www.goldcopd.com; http://www.ersnet.org/
LrPresentations/copd/ﬁles/main/contenu/pages/
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full_text.pdf). The Dutch guidelines [8] recom-
mend treatment for 7 days, and treatment for 7–
10 days is probably common practice.
Recent studies concerning community-acquired
pneumonia have demonstrated that the clinical
effectiveness of treatment with amoxycillin for
3 days is not inferior to that of treatment for
8 days [9] or 5 days [10]. As in the treatment of
AECOPD, eradication of the causative microor-
ganism is not usually achieved [11]; a shorter
duration of treatment could therefore also be an
option for AECOPD. A standard 10-day course of
amoxycillin–clavulanic acid (co-amoxyclav) for
AECOPD has been compared with treatment for
5 days with gatiﬂoxacin [12], telithromycin [13] or
ceftibuten [14], but because both the drug and the
duration of treatment varied, comparison of these
studies is difﬁcult.
If a shorter duration of therapy was also
effective and safe for the treatment of AECOPD,
this could contribute signiﬁcantly to an overall
decrease in the consumption of antibiotics. The
present study describes a randomised, double-
blind multicentre trial designed to compare the
efﬁcacy and safety of a short (3-day) treatment
period with amoxycillin–clavulanic acid with that
of the standard 10-day treatment of hospitalised
patients with AECOPD.
MATERIALS AND METHODS
The study was conducted at six hospitals in The Netherlands.
The institutional review boards at each study centre approved
the study.
Patient selection
Eligible patients were those aged ‡18 years who fulﬁlled
the clinical criteria for COPD, and who presented with
purulent sputum and a type 1 exacerbation, increased
dyspnoea, increased volume and purulence of sputum, or
two of these criteria in a patient with chronic heart failure
[5], and a chest radiograph that showed no evidence of
pneumonia. COPD was deﬁned as a disorder characterised
by abnormal tests of expiratory ﬂow that did not change
markedly during an observation period of several months
[15].
Excluded patients were those with a history of allergy
to amoxycillin–clavulanic acid, neutropenia (<1.0 · 109 ⁄L),
agammaglobulinaemia, cystic ﬁbrosis or bronchiectasis, a
life-expectancy of <1 month, previous treatment with an
effective antimicrobial agent for >24 h before admission, or
any other infection necessitating the administration of
systemic antibiotics. Patients admitted to an intensive care
unit and patients who required ventilation were also
excluded.
Study design
Between November 2000 and December 2003, eligible patients
were invited to participate in the study and were asked to
provide written informed consent. Consenting patients were
treated with amoxycillin–clavulanic acid, either orally or
intravenously. Other treatment decisions, e.g., the criteria for
hospitalisation, treatment with steroids, and oral vs. intraven-
ous antibiotic treatment, were at the discretion of the treating
physician. After treatment for 72 h, four respiratory symptoms
(dyspnoea, cough, production of sputum and colour of
sputum) and general improvement were each rated on a
ﬁve-point symptom scale. The scales extended from )2
(worsening ⁄not recovered) to 3 (completely recovered). Pa-
tients who had improved by two or more points on this scale,
who had a temperature <38C, and who were able to take oral
medication, were randomised to receive either oral amoxy-
cillin–clavulanic acid 625 mg or placebo, four times daily for
7 days. If a causative pathogen was isolated, it was a
requirement that the pathogen was susceptible to amoxycil-
lin–clavulanic acid.
The randomisation scheme was generated centrally using
random tables. Study drugs were distributed to the participa-
ting hospitals in blocks of four, containing amoxycillin–
clavulanic acid and placebo in a ratio of 1:1. All study drugs
were identical in appearance and packaging. Study treatment
was not revealed until the analysis was completed, i.e., after
each case had been classiﬁed as cure, treatment failure ⁄ recur-
rence or indeterminate.
Evaluations
At study entry (day 0), a complete medical history and a
sputum culture were obtained, and a chest radiograph was
taken. COPD-related symptoms (30 days before admission and
at enrolment) were rated using a symptom score. Presence and
severity of shortness of breath were rated on a ﬁve-point scale,
and volume and colour of sputum were rated on a four-point
scale. High values indicated more severe symptoms.
Patients were scheduled for follow-up at days 3 (day of
randomisation), 7, 10, 14 and 21 after study entry. The
following parameters were scored at each follow-up visit:
COPD-related symptoms, prescription of antibiotics other
than study medication, concomitant medication, and the use
of oxygen. A further physical examination, including vital
signs, was performed and a sputum culture was obtained. At
days 0 and 21, serum was collected to determine antibodies
against respiratory viruses. At 3 months, recurrences were
determined by asking the patients by telephone about new or
worsened signs and symptoms of an AECOPD between day
21 and month 3. Drug-related adverse events were recorded
until day 10.
Outcome measures
The primary measures of effectiveness were clinical cure at
day 21, indicated as test of cure (TOC), and at 3 months (late
follow-up). Secondary outcome measures were: microbiologi-
cal success at TOC and late follow-up; symptom recovery; the
duration and cumulative dose of systemic corticosteroids used
(expressed in prednisolone equivalents); the duration of
oxygen therapy; the length of hospital stay; and drug-related
adverse events. Clinical and microbiological response was
classiﬁed using existing guidelines [16] (Table 1).
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Statistical analysis
The study was designed to demonstrate non-inferiority of the
short treatment. Based on an a level of 5% and a power of 0.80,
assuming that 90% of the patients are cured on day 21 [17],
and accepting a difference of 10% at the expense of the short
treatment, it was calculated that a sample size of 225 was
required.
All outcomes were evaluated in an ‘intention-to-treat’
analysis that included all randomised patients who received
at least one dose of the study drug. For the clinical and
microbiological outcomes, indeterminate cases were classed as
failures [16], and failures and indeterminate cases at TOC were
carried forward in the analyses at 3 months.
Microbiological success was deﬁned as demonstrated erad-
ication or presumed eradication (in patients who were cured
clinically), while microbiological failure was deﬁned as per-
sistence, presumed persistence (in patients who were classed
as clinical failures), relapse, re-infection or superinfection. All
other cases were classed as indeterminate for analyses [16].
Microbiological outcome was analysed only for patients who
had a pathogen isolated at study entry.
Differences in success rates were calculated, together with
their 95% CIs. The median symptom scores at each time-point,
the duration and cumulative dose of systemic corticosteroids
used, the duration of oxygen therapy and the length of hospital
stay were calculated. The treatment groups were compared
using the t-test, Mann–Whitney test, or chi-square test, as
appropriate. The safety of each treatment was described by
frequency statistics. Statistical analyses were performed with
SPSS v.11.5.2 software (SPSS Inc., Chicago, IL, USA).
RESULTS
Patients
The required sample size of 225 patients could not
be achieved. The main reason for the recruitment
problems was that many patients received anti-
biotic treatment from their general practitioner
before being admitted, which was an exclusion
criterion. Some patients did not fulﬁl the criteria
for a type 1 exacerbation, most frequently because
they did not produce sputum. Other patients
were admitted to an intensive care unit, and
therefore could not be included in the study. As
no improvement in the inclusion rate was expect-
ed, recruitment was stopped.
During the course of 3 years, 56 patients were
enrolled in the study (Fig. 1). After treatment for
3 days, six patients did not meet the pre-speciﬁed
randomisation criteria, and two patients with-
drew from the study at their own request. The
remaining 48 patients were randomised; 23 were
assigned to the 3-day regimen, and 25 were
assigned to the 10-day regimen. In the 3-day
group, two patients were removed from the
analysis because of a protocol violation; one
patient had a causative pathogen that was not
susceptible to the study drug, and one patient had
an inﬁltrate on the chest radiograph at day 0. The
two excluded patients did not receive any study
medication and were not included in the inten-
tion-to-treat analysis. Thus, in total, 46 patients
were included in the ﬁnal analysis.
The baseline characteristics were comparable for
both treatment groups (Table 2; Fig. 2). A patho-
genwas detected in the sputum of 19 patients, with
more than one pathogen found for four patients.
The pathogens detected most frequently were
Haemophilus inﬂuenzae, Streptococcus pneumoniae
and Moraxella catarrhalis. A recent infection with
inﬂuenza virus A or B was detected in four
patients. None of the patients had bacteraemia.
Primary outcomes
In the intention-to-treat analysis, 16 (76%) of 21
patients in the 3-day treatment group were cured
at TOC, compared with 20 (80%) of 25 patients in
the 10-day treatment group (difference )3.8%;
95% CI )28 to 20). At late follow-up, 13 (62%) of
21 patients in the 3-day treatment group were
cured, compared with 14 (56%) of 25 patients in
the 10-day treatment group (difference 5.9%;
95% CI )23 to 34) (Fig. 3).
Secondary outcomes
Of the patients with a positive sputum culture at
study entry, nine (82%) of 11 patients were micro-
Table 1. Deﬁnitions of clinical response (based on the
criteria of Chow et al. [16])
Clinical response Deﬁnition
TOC, test of cure
Cure The resolution of acute symptoms and signs to a baseline
level of dyspnoea, cough, sputum production and, if
elevated at enrolment,resolution of fever
Failure The absence of any resolution in the magnitude of the
dyspnoea, sputum purulence or fever (if present) that
prompted enrolment of the patient in the study
Indeterminate The patient received, for reasons other than clinical failure,
<80% of the study drug, or acquired a concomitant
infection outside the respiratory tract that required
antibiotic treatment
Follow-up
Cure Continued resolution or improvement of acute symptoms
and signs to a baseline level or reduction of dyspnoea,
cough and sputum production and, if elevated at enrolment,
resolution of fever
Recurrence New or worsened signs and symptoms of an exacerbation
of COPD in a patient who was cured at the TOC visit
Indeterminate A concomitant infection outside the respiratory tract
that required antibiotic treatment, or death unrelated
to the primary diagnosis
COPD, chronic obstructive pulmonary disease.
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biologically cured at TOC in the 3-day treatment
group, comparedwith six (75%) of eight patients in
the 10-day treatment group. Four patients were
classiﬁed as microbiological failures: two patients
in the 3-day treatment group had a relapsewithout
clinical symptoms; one patient in the 10-day treat-
ment group had a superinfection with clinical
symptoms; and one patient in the 10-day treatment
group was classed as indeterminate, because of
antibiotic treatment received for protastitis. At
3 months, the microbiological cure rates were
eight (73%) of 11 patients in the 3-day treatment
group, compared with ﬁve (62%) of eight patients
in the 10-day treatment group. Two patients, one
in each treatment group, had a recurrence; anti-
biotic therapy was started in the absence of micro-
biological data, and these cases were classed as
microbiological failures.
Included (n = 56) 
Not randomised (n = 8): 
- no significant improvement (n = 3) 
- pathogen not susceptible to the study drug 
  (n = 3)
- withdrawn from study at request of patient 
   and/or family (n = 2) 
Randomised after 3 days 
of co-amoxyclav (n= 48)  
Allocated to additional 
7-day co-amoxyclav (n= 25) 
Allocated to additional 
7-day placebo (n= 23)
Indeterminate (n= 3): 
- concomitant infection, treated 
  with antibiotics (n= 2)
- withdrawn from study at 
   request of physician (n= 1) 
Indeterminate (n= 2): 
- withdrawn from study  
  at own request (n= 2) 
Cure or improvement at 3 weeks (n= 20) 
Failed (n= 2): 
- worsening of signs and 
  symptoms and resumed antibiotics 
  (n= 2) 
Failed (n= 3): 
- worsening of signs and  
  symptoms and restart 
  antibiotics (n= 3) 
Cure or improvement at 3 weeks  (n= 16)
Cure or improved at 3 months (n= 14) Cure or improved at 3 months (n= 13) 
Recurrence (n= 5): 
- worsening of signs and 
  symptoms and restart of antibiotics 
  (n= 2) 
- worsening of signs and  
  symptoms and readmission to 
  hospital (n=3)
Indeterminate (n= 1): 
- death unrelated to COPD (n= 1) 
Recurrence (n= 2): 
- worsening of signs and 
  symptoms and restart  
  antibiotics (n= 2) 
Indeterminate (n= 1): 
- concomitant infection, treated 
  with antibiotics (n= 1)
Protocol violation (n= 2)
- pathogen not susceptible to 
  the study drug  (n= 1)
- pneumonia (n= 1) 
Analysed (n= 21)  
Fig. 1. Trial proﬁle (COPD, chronic obstructive pulmonary disease; co-amoxyclav, amoxycillin-clavulanic acid).
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At each time-point during follow-up, the scores
of the COPD-related symptoms in both treatment
groups were similar (Fig. 2). Upon admission,
scores for shortness of breath, and volume and
colour of sputum, were higher than the pre-
exacerbation scores at 30 days before enrolment.
The scores for shortness of breath and sputum
volume returned to the pre-exacerbation scores at
day 3; the score for sputum colour returned to the
pre-exacerbation score at day 7.
In total, 42 (91%) patients were prescribed
systemic steroids, as can be expected for hospi-
talised patients. Systemic corticosteroids were
used for a median of 12 days (inter-quartile range
(IQR) 7–18 days) in the 3-day treatment group,
compared with 14 days (IQR 8–21 days) in the
10-day treatment group (p 0.31). The cumulative
dose of prednisolone equivalents was 333 mg in
the 3-day treatment group (IQR 185–443 mg),
compared with 415 mg (IQR 343–593 mg) in the
10-day treatment group (p 0.05). Oxygen was
used for a median of 3 days (IQR 0–7 days) in the
3-day treatment group, compared with 7 days
(IQR 0–7 days) in the 10-day treatment group
(p 0.77); the median length of hospital stay was
9 days (IQR 7.5–10 days) in the 3-day treatment
group, compared with 9 days (IQR 6.5–12.0 days)
in the 10-day treatment group (p 0.86). Adverse
events until day 10 of treatment were reported by
one patient in the 3-day-treatment group, and by







Male 10 (48) 16 (64)
Female 11 (52) 9 (36)
Age, years
Median (IQR) 69 (59–76) 66 (61–71)
Classiﬁcation of COPD by severity, n (%)
GOLD I 2 (9) 3 (12)
GOLD II 10 (48) 8 (32)
GOLD III, IV 9 (43) 14 (56)
Daily medication, n (%)a
None 3 (14) 3 (12)
b2-Agonists ⁄ anti-cholinergics 6 (29) 6 (24)
ICs (± b2-agonists ⁄ anti-cholinergics) 11 (52) 16 (64)
Underlying diseaseb, n (%) 12 (57) 16 (64)
Diabetes mellitus 3 (14) 6 (24)
Cardiovascular disease 9 (43) 12 (48)
Malignancy 4 (19) 0 (0)
Smoking, n (%) 10 (48) 15 (60)
Temperature >37.5C, n (%) 11 (52) 14 (56)
Symptom scores, median (IQR)c
Shortness of breath 2 (2–3) 3 (2–3)
Sputum volume 2 (1–2) 2 (1–2)
Sputum colour 2 (1–3) 2 (1–3)
Detected pathogen at study entryd, n
Haemophilus inﬂuenzae 5 5
Streptococcus pneumoniae 5 2
Moraxella catarrhalis 3 2
Escherichia coli 1 0
Candida albicans 0 1
Inﬂuenza virus A ⁄B 1 3
Respiratory syncytial virus 0 1
Mycoplasma pneumoniae 0 1
GOLD, Global Initiative for Chronic Obstructive Lung Disease (http://www.gold
copd.com); ICs, inhaled corticosteroids; COPD, chronic obstructive pulmonary
disease; IQR, inter-quartile range.
aOne patient was receiving theofylline.
bSome patients had more than one underlying disease.
cShortness of breath was rated on a ﬁve-point scale; volume and colour of the
sputum are both rated on a four-point scale. High values indicate more severe
symptoms.






































Fig. 2. Symptom scores for both treatment groups. The symptom scores of both treatment groups are expressed as
medians and inter-quartile ranges. Day )30 represents the pre-exacerbation level; day 0 is the day of starting antibiotic
therapy; day 21 is test of cure.
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ﬁve patients in the 10-day treatment group
(p 0.11). All the adverse events reported were
mild and were related to the gastrointestinal
tract.
DISCUSSION
In this multicentre, placebo-controlled, double-
blind trial, the early and late cure rates obtained
following treatment with amoxycillin–clavulanic
acid for 3 days were comparable to those
obtained following treatment with the standard
10-day regimen for hospitalised patients with
AECOPD who have improved after initial ther-
apy for 3 days, although a clinically relevant
difference could not be excluded. The microbio-
logical results, symptom recovery, the use of
systemic corticosteroids and oxygen, length of
hospital stay and reported adverse events were
also comparable for both groups.
The strengths of this study were the double-
blind, randomised design and the fact that only
patients who required antibiotic therapy (i.e.,
those with a type 1 exacerbation) were included
in the study [4–6]. No previous studies comparing
short- and long-term treatment durations with
amoxycillin–clavulanic acid have been published,
but studies in which amoxycillin–clavulanic acid
for 10 days was compared with a shorter duration
of an alternative antibiotic also showed equal
efﬁcacy for the short treatment [12–14].
The major limitation of this study was the
limited number of patients. Although no differ-
ences in clinical cure rates, or in any of the
secondary endpoints, were found among patients
in the 3-day and 10-day treatment groups, the
conﬁdence intervals were wide. Given the extent
of antibiotic consumption associated with exacer-
bations of COPD, which is endorsed by guidelines
and a recent Cochrane analysis [18], a larger study
is clearly indicated.
At a population level, there is a clear rela-
tionship between total antibiotic consumption
and resistance rates among pathogens. Respir-
atory tract infections are the main indications
for antibiotic use in the community [19], and
AECOPD contributes to this on a large scale. In
recent years, resistance rates among common
respiratory pathogens for a number of
antimicrobial agents have clearly increased
20–24]. To address this problem, new antimi-
crobial agents have been tested and have been
found to be clinically and bacteriologically
effective [25–27]. However, restricted use of
the antibiotics available currently could be a
more efﬁcient alternative. A shorter duration of
treatment might diminish overall antibiotic use,
and thereby contribute to the containment of the
growing resistance rates among respiratory
pathogens.
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